- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Important, 27-11-2025: Updates
27-11-2025 | 08:23 am
27-11-2025 | 08:23 am
Biocon Biologics' Bengaluru Drug Substance Facility received a US FDA Voluntary Action Indicated (VAI) classification post-inspection. This positive outcome for rh-Insulin and Biosimilar Pegfilgrastim manufacturing for the US market signals strong compliance.
No comments yet. Be the first to comment!